---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-039554"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T08:05:48.812279+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NRx Pharma reports FY2022 net loss $39.8M; advances NRX-101 trials, issues going concern warning

## Summary
- Net loss $39.8M for FY2022 vs $93.1M prior year; R&D $17.0M, G&A $27.4M.
- Cash $20.1M at Dec 31, 2022; raised $2.9M in March 2023 registered direct offering.
- DSMB cleared NRX-101 Phase 2b/3 trial for suicidal treatment-resistant bipolar depression; topline data expected 4Q2023.
- FDA suggested broader outpatient indication for NRX-101; safety database of 1,500 patients required.
- Going concern doubt: no revenue, $11M note to Streeterville Capital may require cash repayment; additional financing needed.

## SEC filing metadata
- accession: 0001104659-23-039554
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465923039554/0001104659-23-039554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465923039554/tm2311032d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-039554
- JSON: https://secwatch.observer/filing/0001104659-23-039554.json
- Plain text: https://secwatch.observer/filing/0001104659-23-039554.txt

## Key facts
- Earnings Releases
  NRX Pharmaceuticals, Inc. reported financial results for full year and fourth quarter ended December 31, 2022.
  - Period: full year and fourth quarter ended December 31, 2022
  - Result: reported results
  source text: On March 30, 2023, the Company announced its financial results for the full year and fourth quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465923039554/0001104659-23-039554-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.